Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study.
mobile phone
multiple sclerosis
patient adherence
patient satisfaction
smartphone
wearable electronic devices
Journal
Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882
Informations de publication
Date de publication:
30 08 2019
30 08 2019
Historique:
received:
11
06
2019
accepted:
19
07
2019
revised:
11
07
2019
entrez:
1
9
2019
pubmed:
1
9
2019
medline:
21
5
2020
Statut:
epublish
Résumé
Current clinical assessments of people with multiple sclerosis are episodic and may miss critical features of functional fluctuations between visits. The goal of the research was to assess the feasibility of remote active testing and passive monitoring using smartphones and smartwatch technology in people with multiple sclerosis with respect to adherence and satisfaction with the FLOODLIGHT test battery. People with multiple sclerosis (aged 20 to 57 years; Expanded Disability Status Scale 0-5.5; n=76) and healthy controls (n=25) performed the FLOODLIGHT test battery, comprising active tests (daily, weekly, every two weeks, or on demand) and passive monitoring (sensor-based gait and mobility) for 24 weeks using a smartphone and smartwatch. The primary analysis assessed adherence (proportion of weeks with at least 3 days of completed testing and 4 hours per day passive monitoring) and questionnaire-based satisfaction. In-clinic assessments (clinical and magnetic resonance imaging) were performed. People with multiple sclerosis showed 70% (16.68/24 weeks) adherence to active tests and 79% (18.89/24 weeks) to passive monitoring; satisfaction score was on average 73.7 out of 100. Neither adherence nor satisfaction was associated with specific population characteristics. Test-battery assessments had an at least acceptable impact on daily activities in over 80% (61/72) of people with multiple sclerosis. People with multiple sclerosis were engaged and satisfied with the FLOODLIGHT test battery. FLOODLIGHT sensor-based measures may enable continuous assessment of multiple sclerosis disease in clinical trials and real-world settings. ClinicalTrials.gov: NCT02952911; https://clinicaltrials.gov/ct2/show/NCT02952911.
Sections du résumé
BACKGROUND
Current clinical assessments of people with multiple sclerosis are episodic and may miss critical features of functional fluctuations between visits.
OBJECTIVE
The goal of the research was to assess the feasibility of remote active testing and passive monitoring using smartphones and smartwatch technology in people with multiple sclerosis with respect to adherence and satisfaction with the FLOODLIGHT test battery.
METHODS
People with multiple sclerosis (aged 20 to 57 years; Expanded Disability Status Scale 0-5.5; n=76) and healthy controls (n=25) performed the FLOODLIGHT test battery, comprising active tests (daily, weekly, every two weeks, or on demand) and passive monitoring (sensor-based gait and mobility) for 24 weeks using a smartphone and smartwatch. The primary analysis assessed adherence (proportion of weeks with at least 3 days of completed testing and 4 hours per day passive monitoring) and questionnaire-based satisfaction. In-clinic assessments (clinical and magnetic resonance imaging) were performed.
RESULTS
People with multiple sclerosis showed 70% (16.68/24 weeks) adherence to active tests and 79% (18.89/24 weeks) to passive monitoring; satisfaction score was on average 73.7 out of 100. Neither adherence nor satisfaction was associated with specific population characteristics. Test-battery assessments had an at least acceptable impact on daily activities in over 80% (61/72) of people with multiple sclerosis.
CONCLUSIONS
People with multiple sclerosis were engaged and satisfied with the FLOODLIGHT test battery. FLOODLIGHT sensor-based measures may enable continuous assessment of multiple sclerosis disease in clinical trials and real-world settings.
TRIAL REGISTRATION
ClinicalTrials.gov: NCT02952911; https://clinicaltrials.gov/ct2/show/NCT02952911.
Identifiants
pubmed: 31471961
pii: v21i8e14863
doi: 10.2196/14863
pmc: PMC6743265
doi:
Banques de données
ClinicalTrials.gov
['NCT02952911']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14863Commentaires et corrections
Type : ErratumIn
Informations de copyright
©Luciana Midaglia, Patricia Mulero, Xavier Montalban, Jennifer Graves, Stephen L Hauser, Laura Julian, Michael Baker, Jan Schadrack, Christian Gossens, Alf Scotland, Florian Lipsmeier, Johan van Beek, Corrado Bernasconi, Shibeshih Belachew, Michael Lindemann. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 30.08.2019.
Références
Clin Rehabil. 2017 Sep;31(9):1215-1225
pubmed: 28786335
Mult Scler J Exp Transl Clin. 2016 Mar 4;2:2055217316634754
pubmed: 28607720
Mult Scler. 2017 Dec;23(14):1929-1937
pubmed: 28080262
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Can J Public Health. 1992 Jul-Aug;83 Suppl 2:S7-11
pubmed: 1468055
J Vis Exp. 2014 Jun 30;(88):e51318
pubmed: 25046650
J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):701-4
pubmed: 12438473
Front Neurol. 2018 Sep 04;9:740
pubmed: 30233487
Mult Scler Relat Disord. 2018 May;22:90-96
pubmed: 29649789
Health Technol Assess. 2009 Feb;13(12):iii, ix-x, 1-177
pubmed: 19216837
IEEE J Biomed Health Inform. 2017 Sep;21(5):1376-1385
pubmed: 27455529
Mult Scler. 2009 Dec;15(12):1509-17
pubmed: 19995840
Neurol Clin. 2010 May;28(2):395-410
pubmed: 20202500
Neurol Neuroimmunol Neuroinflamm. 2015 Oct 15;2(6):e162
pubmed: 26516627
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Mov Disord. 2018 Aug;33(8):1287-1297
pubmed: 29701258
Brain. 2001 May;124(Pt 5):962-73
pubmed: 11335698
J Hand Ther. 2015 Jan-Mar;28(1):53-9; quiz 60
pubmed: 25449717
Mult Scler. 2013 Aug;19(9):1240-1
pubmed: 23388164
BMC Neurol. 2013 Apr 25;13:37
pubmed: 23617555
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Mult Scler. 2018 Nov;24(13):1657-1664
pubmed: 30231004
Neurol Clin Pract. 2017 Aug;7(4):354-362
pubmed: 29185551